GlassScriptPhysician profile
Sanjeevkumar A Patel
NPI 1033422860
$6,359.43
in general payments reported to CMS, 2019-2025
14 companies · $414 in 2025
The $414 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $299 · 2021: $740 · 2022: $16.79 · 2023: $78.05 · 2024: $4,812 · 2025: $414.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,600 · Travel and Lodging: $1,854 · Food and Beverage: $850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,599.95 |
| Travel and Lodging | $1,853.93 |
| Food and Beverage | $849.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $4,675.36 | 2024 | |
| Ethicon INC. | $1,038.77 | 2019-2021 | |
| United Therapeutics Corporation | $125.00 | 2025 | |
| Inogen, INC. | $124.98 | 2022-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Galvanize Therapeutics, INC | $83.28 | 2025 | Aliya System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.43 | 2025 | Jascayd |
| Verona Pharma, INC. | $31.57 | 2025 | Ohtuvayre |
| Glaxosmithkline, LLC. | $29.31 | 2024-2025 | Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $24.92 | 2025 | Glassia |
| Astrazeneca Pharmaceuticals LP | $21.28 | 2024 | |
| Grifols USA, LLC | $19.22 | 2025 | Prolastin-C Liquid |
| Jazz Pharmaceuticals INC. | $14.56 | 2025 | |
| Insmed, INC. | $13.80 | 2025 | Arikayce |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sanjeevkumar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.